Evidence map›Paper›PMID 36629422›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

New cyclopentaquinoline and 3,5-dichlorobenzoic acid hybrids with neuroprotection against oxidative stress for the treatment of Alzheimer's disease.

Kamila Czarnecka, Małgorzata Girek, Paweł Kręcisz, Robert Skibiński, Kamil Łątka, Jakub Jończyk, Marek Bajda, Piotr Szymczyk, Grzegorz Galita, Jacek Kabziński and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Determination of Potential Lead Compound fromInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Kamila CzarneckaDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Małgorzata GirekDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Paweł KręciszDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Robert SkibińskiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.
Kamil ŁątkaDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
Jakub JończykDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
Marek BajdaDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.ORCID 0000-0001-6032-0354
Piotr SzymczykDepartment of Biology and Pharmaceutical Botany,Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Grzegorz GalitaDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Lodz, Poland.
Jacek KabzińskiDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Lodz, Poland.
Ireneusz MajsterekDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Lodz, Poland.
Alba EspargaróDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
Raimon SabateDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
Paweł SzymańskiDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland.
Medical University of Lodz · PLJagiellonian University · PLInstitut de Nanociència i Nanotecnologia de la Universitat de BarcelonaMedical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative brain disease. Thus, drugs including donepezil, rivastigmine, and galantamine are not entirely effective in the treatment of this multifactorial disease. The present study evaluates eight derivatives (

Indexed as

Alzheimer DiseaseNeuroprotective AgentsAcetylcholinesteraseChlorobenzoatesCholinesterase InhibitorsHumansNeuroprotectionOxidative Stress3,5-dichlorobenzoic acidAcetylcholinesteraseChlorobenzoatesCholinesterase InhibitorsNeuroprotective Agentsacetylcholinesterase inhibitorsAlzheimer’s diseaseEllman’s methodmolecular modellingMTDL

Identifiers

PMID36629422
PMCPMC9848259
OpenAlexW4315620512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.